PayerTalkCE Presents: Applying Real-World Experience to Better Manage the Use of Oncology Biosimilars Web Activity

Release Date: December 1, 2022 Expiration Date: May 31, 2024 Estimated Time to Complete Activity: 1.0 hour Compatible with all modern browsers and mobile devices

Expert Faculty Author:

Raj W. Duggal, PharmD, BCOP Clinical Manager - Oncology Pharmacy Indiana University Health Click here for biography James T. Kenney, RPh, MBA President JTKENNEY, LLC Click here for biography Cate Lockhart, PharmD, PhD Executive Director Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, specialty pharmacists, care managers, registered nurses, and other managed care and payer organization professionals.

Statement of Need/Program Overview
Real-world experience (RWE) has long been used to inform decisions about access and reimbursement policies. However, RWE strategies are not consistently applied to manage the use of biosimilars in oncology care that may improve patient access and without equivalent coverage in payer reimbursement policies, biosimilars stand at a significant access disadvantage compared to reference products and patients will struggle to gain access to these high-quality, potentially lower-cost treatment options. In many cases, utilization management data can be combined with clinical data gleaned from the EHR to provide a more robust view into the relationship between payer policies and clinical outcomes. With the ability to track patients over time, RWE can help provide managed care and payer stakeholders a more comprehensive view of patient response to biosimilars that can be used to inform future clinical decisions, as well as access, coverage, and reimbursement policies.

Educational Objectives
After completing this activity, the participant should be better able to:

• Identify key considerations associated with adoption of oncology biosimilars for the treatment of lymphoma, colorectal, lung, and breast cancer
• Discuss the use of real-world experience (RWE) including implementation, switching, and health economic data to address evidence gaps and reduce barriers to biosimilar utilization
• Apply RWE payer strategies to manage the use of biosimilars in oncology care and improve patient access to high quality care

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional continuing Education (IPCE) credit for learning and change.

Physician Credit
Medical Education Resources designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
Medical Education Resources designates this live activity for a maximum of 1.0 ANCC nursing contact hour. Nurses will be awarded contact hours upon successful completion of the activity.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hour.

Pharmacy Credit
Medical Education Resources (MER) designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA000368--9999-22-035-H01-P
This activity is certified as Knowledge-based CPE

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure of Conflicts of Interest
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are mitigated by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Pfizer, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period December 1, 2022, through May 31, 2024, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.